Table 1.

Study and patients’ characteristics

Authors	Year	Country	Study design	Patients*	PET tracer	Iodine isotope for mIBG	NB	Children/adolescents and adults	Staging/restaging	SOR
Shulkin et al. [14]	1996	USA	R	6	[11C]C-HED	[123I]	6 HR*	5/1	6/0	CT and MRI
Franzius et al. [15]	2006	Germany	R	7	[11C]C-HED	[123I]	3 HR*	6/1	3/4	Histology and CT
Piccardo et al. [16]	2012	Italy	P	19	[18F]F-DOPA	[123I]	17 HR*	17/2	4/15	Histology, CT and MRI
Lu et al. [20]	2013	Taiwan	R	18	[18F]F-DOPA	[123I]	N.R	18/0	N.R	Histology
Piccardo et al. [13]	2020	Italy	P	18	[18F]F-DOPA	[123I]	16 HR*	18/0	18/0	Histology, CT and MRI
Hemrom et al. [17]	2022	India	R	46	[18F]F-DOPA	[131I]	N.R	46/0	42/4	N.R
Aboian et al. [18]	2021	USA	R	8	[124I]mIBG	[123I]	8 HR*	N.R	0/8	cross-sectional imaging
Pandit-Taskar et al. [22]	2018	USA	P	5	[18F]mFBG	[123I]	N.R	N.R	0/5	N.R
Samim et al. [19]	2023	Netherlands	P	14	[18F]mFBG	[123I]	14 HR*	11/3	5/9	N.A
Wang et al. [21]	2023	China	P	40	[18F]mFBG	[123I]	33 HR*	NR	3/37	Histology, CT and MRI

^*Included only those patients who performed both mIBG and PET with one of the catecholaminergic tracers

^**HR High Risk Neuroblastomas

NR Not reported, N/A Not available

R retrospective, P prospective